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Background: The burden of catheter-related infections (CRIs) in developing countries is severe. In South Africa, a
standardised surveillance definition does not exist and the collection of catheter days is challenging. The aim of the
study was to provide baseline data on the prevalence of CRIs and to describe the epidemiology of CRI events
within a tertiary academic hospital.
Methods: Surveillance was laboratory-based and conducted for a six month period. A microbiologically confirmed
CRBSI (MC-CRBSI) event was defined as the isolation of the same microorganism from the catheter and concomitant
blood cultures (BCs), within 48 h of catheter removal, which were not related to an infection at another site.
Results: A total of 508 catheters, removed from 332 patients, were processed by the laboratory, of which only 50%
(253/508 removed from 143/332 patients) of the catheters were accompanied by BCs within 48 h. Sixty-five episodes of
MC-CRBSI in 57 patients were detected, involving 71 catheters and 195 microbial isolates. The institutional prevalence
rate was 3.7 episodes per 1 000 admissions and 5.8 episodes per 10 000 in-patient days. Catheter day data was collected
in only six wards of the hospital. The pooled laboratory incidence was 10.1 MC-CRBSI episodes per 1 000 catheter days,
whereas the hospital-based central line-associated bloodstream infection (CLABSI) rate was pooled at 5.7 episodes
per 1 000 catheter days. The majority of patients had an underlying gastro-intestinal condition (33%; 19/56) with a
non-tunnelled, triple-lumen central venous catheter, placed in the subclavian vein (38%; 27/71). The most
predominant pathogen was methicillin-resistant Staphylococcus epidermidis (28%; 55/195), followed by
extensively-drug resistant Acinetobacter baumannii (18%; 35/195).
Conclusions: Catheter-related infection prevention and control efforts require urgent attention, not only to keep
patients safe from preventable harm, but to prevent the spread of multidrug resistant microorganisms.
Keywords: Healthcare-associated infections, Catheter-related infections, Catheter-related bloodstream infections,
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Catheter-related infections [CRI(s)] in sub-Saharan Africa
pose a significant threat to a hospitalized patient’s safety
[1,2]. Not only are CRIs associated with increased mortal-
ity, these infections contribute an increased length of hos-
pital stay and increased healthcare costs, which is
problematic in a limited-resource setting, such as South
Africa [3,4].* Correspondence: wilkestrasheim@gmail.com
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unless otherwise stated.A focus on education and strict adherence to infection
prevention and control programmes are associated with
a reduction in CRI rates [5]. However, the first step in
reducing CRIs, prior to the implementation of education
and prevention programmes, is to define the extent of the
problem through surveillance [4,6]. Effective surveillance
measures are dependent on the adoption of a standardised
case definition [7]. However, there is lack of uniformity of
the case definition of a CRI among different organisations
in various geographical locations [8-11].ral. This is an Open Access article distributed under the terms of the Creative
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and child health are national priorities and the improve-
ment of patient safety and healthcare quality has only re-
cently been identified as important [12]. Surveillance of
healthcare-associated infections and the accompanying
definitions are therefore not yet established in South
Africa [13]. In 2009, the “Best Care…Always!” (BCA) ini-
tiative was launched to increase the implementation
speed of quality improvements throughout healthcare fa-
cilities and the campaign adopted a simplified version of
the United States of America’s Centers of Disease Control
and Prevention’s National Healthcare Safety Network’s
(CDC/NHSN’s) definition [14].
However, the CDC/NHSN’s definition might not be
ideal for the situation in South Africa, since it requires
extensive education and training, is laborious and sub-
jective [15]. In addition, South Africa is facing a national
shortage of nursing staff and the collection of denomin-
ator data (i.e. the number of catheter days) is a huge
challenge [3,16,17]. A simplified laboratory-based defin-
ition might be an alternative surveillance measure as
suggested by Rodríguez-Créixems and colleagues, since
the data is readily available and can be reported against
a denominator of either patient admissions or in-patient
days [18].
The aim of the study was to provide baseline data on
CRIs from laboratory records and to describe patient,
catheter and pathogen characteristics of CRI events
within a tertiary academic hospital in South Africa. This
is the first report, to the extent of the authors’ know-




The observational study was laboratory-based. Only
intravascular catheters submitted with concomitant blood
culture(s) [BC(s)] received from a tertiary academic hos-
pital, during May to October 2013, were included. The
832-bed hospital acts as a referral hospital in the region;
providing specialised services to the public.
Data collection and definitions
Laboratory surveillance was conducted in accordance
with the Infectious Diseases Society of America’s and the
Irish’s national CRI committee’s definitions [11,19].
Briefly, a microbiologically confirmed catheter-related
bloodstream infection (MC-CRBSI) was defined as a
bloodstream infection occurring within 48 h of catheter
removal and the subsequent isolation of the same micro-
organism from the catheter culture as on the BC(s) [11].
Additional criteria were added to include events caused
by common commensals, such as Staphylococcus epider-
midis, in which only a single BC bottle flagged positive[19]. The genetic relationship between catheter tip and
BC isolates of common commensals were confirmed
with pulsed-field gel electrophoresis. Catheter tip and
BC isolates were considered identical, if the pulsotype’s
banding patterns showed ≥ 80% similarity (Applied
Maths, Kortrijk, Belgium). The event was excluded if the
similarity values were < 80% (Results not shown).
Patient and catheter details were collected retrospect-
ively. Patient details included: i) underlying clinical condi-
tion, ii) length of hospitalisation up and to the MC-CRBSI
event, iii) length of catheterisation (number of days elapsed
from catheter insertion to catheter removal), iv) antimicro-
bial exposure, v) chronic illness (HIV, diabetes, renal fail-
ure) and vi) other risk factors (malnutrition, loss of skin
integrity, neutropenia, total parental nutrition administra-
tion) associated with CRIs. Catheter details included: i)
type of vessel occupied, ii) insertion site, iii) physical
length of the catheter (long or short) and iv) any special
characteristics associated with the catheter, such as the
presence of cuffs, antimicrobial impregnation and the
number of lumens.
The aetiological agent(s) of an event and it’s accompan-
ied antimicrobial susceptibility pattern were also recorded.
Multidrug-resistance (MDR), extensively drug-resistance
(XDR) and pandrug-resistance (PDR) were defined for the
six most prevalent bacteria according to international
standards [20].
Laboratory procedures
Blood cultures were processed using the BacT/ALERT
3D system (bioMérieux, France). Quantitative BCs are
not performed routinely in the microbiology laboratory
and MC-CRBSI diagnosed by differential time to positivity
was excluded, due to labelling issues. Catheters were cul-
tured according to a semi-quantitative method [21]. The
growth of ≥15 colony forming units (cfu) was regarded as
significant. All positive catheter and BCs were further
managed according to standard microbiological proce-
dures. Identification and antimicrobial susceptibility test-
ing of microbial isolates were performed with the VITEK®
2 system (bioMérieux, France). Isolates showing inter-
mediate susceptibility were considered resistant.
Statistical analysis
Data recording and statistical analysis were performed
using Excel (Microsoft, Redmond, Washington, USA).
Categorical variables were reported as numbers and per-
centages, whereas continuous variables were reported as
means and standard deviations. The incidence (i.e. the
number of new cases divided by the population at risk,
which is only catheterised patients) of MC-CRBSI was
expressed as the total number of episodes per 1 000
catheter days and was calculated by dividing the total
number of MC-CRBSI episodes with the total number of
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the number of cases divided by the population) of MC-
CRBSI was expressed as the total number of episodes
per 1 000 patient admissions, as well as per 10 000 in-
patients days and was calculated by dividing the total
number of MC-CRBSI episodes with the total number of
patients admitted or the total number of in-patient days,
multiplied by 1 000 or 10 000, respectively.
Ethical approval
Ethical approval was obtained from the Faculty of Health
Sciences Research Ethics Committee of the University of
Pretoria (Protocol number: 118/2013). Informed consent
was waivered, since the study was observational and pa-
tient care was not influenced.
Results
Episodes of MC-CRBSI
A total of 508 catheter tips removed from 332 patients
were processed by the microbiology laboratory during
the six month study period. Only 50% of the catheters
(253/508 removed from 143/332 patients) were accom-
panied by BCs within 48 h. A total of 65 episodes of
MC-CRBSI in 57 patients were identified. The overall
prevalence for the institution was calculated at 3.7 epi-
sodes per 1 000 admissions (65 episodes ÷ 17 559 ad-
missions × 1 000) and 5.8 per 10 000 in-patient days (65
episodes ÷ 112 452 in-patient days × 10 000).
The number of catheter days was only available for six
wards in the hospital, which is currently under BCA sur-
veillance. The MC-CRBSI pooled incidence density was
calculated at 10.1 episodes per 1 000 catheter days forTable 1 Comparision between hospital-based CLABSI rates an
Ward A B
Hospital-based surveillance
Number of CLABSI* events 0 5
CLABSI incidence per 1 000 catheter days 0 5.6
Laboratory-based surveillance
Number of catheters submitted for culture 85 49
Number of catheters accompanied by BCs 44 10
Number of MC-CRBSI events 10 2
MC-CRBSI incidence per 1 000 catheter days 12.9 2.2
MC-CRBSI prevalence per 1 000 admissions 30.1 11.2
Denominators#
Number of central line days 776 891
Number of patient admissions 332 179
A = High care, multidisciplinary ward; B = Neurosurgery ICU; C = Trauma and Surge
F = Paediatric Medical ICU.
CLABSI = central line-associated bloodstream infection; BCs = blood cultures; MC-CR
*CLABSI definition from Best Care…Always! = Occurrence of a primary bloodstream
within 48 h of the removal of the central line, where no other possible source of th
#The number of in-patient days was only available for the hospital as a whole and cthese six wards (44 episodes ÷ 4 373 catheter days × 1
000). The reported CLABSI rate by the BCA campaign for
the corresponding period was pooled at 5.7 episodes per 1
000 catheter days (25 episodes ÷ 4 373 catheter days × 1
000). The relationship between the number of catheters
submitted for culture; the number of catheters accompan-
ied by BCs within 48 h; the BCA campaign’s CLABSI rate
and the laboratory MC-CRBSI rate are shown in Table 1.
Thirty-two percent (32.3%; 21/65) of MC-CRBSI epi-
sodes were detected in non-surveillance wards, which
included: i) paediatric surgery (38.1%; 8/21), ii) general
surgery (14.3%; 3/21), iii) oncology (6.5%; 2/21), iv)
nephrology/peritoneal (6.5%; 2/21), v) neonatal intensive
care unit (ICU) (6.5%; 2/21), vi) vascular surgery (4.8%;
1/21), vii) neurosurgical (4.8%; 1/21), viii) urology and
gynaecology (4.8%; 1/21) and ix) plastic/maxillofacial/
ophthalmology (4.5%; 1/21).
Clinical details of the patients
The clinical characteristics of the patients are sum-
marised in Table 2. Six patients had multiple MC-CRBSI
episodes. Each of these episodes occurred in the same
location as the first event, but a different microorganism
was responsible and occurred within 18.9 days (standard
deviation (SD) = ± 11 days) of another. Six patients were
HIV-positive, two patients were exposed to HIV and the
HIV-status was unknown for two patients. Eighty-nine
percent (89.5%; 51/57) of patients had been exposed to
one or more antimicrobial agent (Table 3). A total of
31% (40/131) of antimicrobial exposures were with last-
resort antimicrobial agents (e.g. glycopeptides, linezolid,
tigecycline and colistin).d laboratory-based MC-CRBSI rates
C D E F Pooled
5 7 7 1 25
4.9 7.7 11.3 6.5 5.7
88 70 19 8 319
77 52 6 8 197
13 12 3 4 44
12.7 13.2 4.9 25.8 10.1
65.6 122.5 19.6 22 38.5
1023 912 617 155 4374
198 98 153 182 1142
ry ICU; D = Medical and Pulmonology ICU; E = Cardiothoracic ICU;
BSI = microbiologically confirmed catheter-related bloodstream infection.
infection in a patient with a central line in situ or where infection occurs
e bloodstream infection could be identified.
ould therefore not be broken down per ward.
Table 2 Patient demographics, underlying conditions, chronic illnesses and risk factors for MC-CRBSI events
Adults % (n = 40) Children % (n = 5) Infants % (n = 12)
Number of MC-CRBSI episodes per patient
1 87.5 (35) 80.0 (4) 100.0 (12)
2 10.0 (4) - -
3 2.5 (1) 20.0 (1) -
Demographics
Mean age (±SD) 44 years (±14.9) 4 years (±3.16) 31 days (±21.4)
% Male 42.5 (17) 100.0 (5) 66.7 (8)
Underlying conditions^
Gastro-intestinal 27.5 (11) 20.0 (1) 58.3 (7)
Nephrology 22.5 (9) - -
Trauma 10.0 (4) - 8.3 (1)
Dermatology (includes burned patients) 7.5 (3) 40.0 (2) -
Surgery (amputation) 7.5 (3) - -
Respiratory 5.0 (2) - 25.0 (3)
Malignancy 5.0 (2) 20.0 (1) 8.3 (1)
Neurologic 5.0 (2) - -
Cardiovascular 2.5 (1) 20.0 (1) -
Endocrinology 2.5 (1) - -
Gynaecology 2.5 (1) - -
Unknown 2.5 (1) - -
Days of hospitalisation# (mean) (±SD) 29.0 (±22.2) 30.0 (±19.3) 27.1 (±14.9)
Unknown per number of events % (n) 13.3 (6/45) 14.3 (1/7) 16.6 (2/12)
Chronic illness^
None 57.5 (23) 80.0 (4) 83.3 (10)
Renal failure 22.5 (9) - -
HIV-positive 12.5 (5) 20.0 (1) (2 exposed)
Diabetes 12.5 (5) - -
Unknown 2.5 (1) - -
Risk factors^
None 40.0 (16) - 50.0 (6)
TPN administration 42.5 (17) 40.0 (2) 33.3 (4)
Malnutrition 12.5 (5) 20.0 (1) -
Loss of skin integrity 7.5 (3) 40.0 (2) 8.3 (1)
Neutropenia 2.5 (1) 20.0 (1) 8.3 (1)
Unknown 2.5 (1) - -
Length of catheterisation 11.1 (±5.5) 15.7 (±6.1) 11.9 (±2.5)
Unknown per number of catheters % (n) 21.6 (11/51) 14.3 (1/7) 33.3 (4/12)
SD = standard deviation; TPN = total parenteral nutrition.
^Incomplete clinical details for a single patient, six patients (five adults and one child) had more than two risk factors present at once, which will explain why
percentages do not add up to 100%.
#the mean length of hospitalisation was calculated for each MC-CRBSI event in patients with multiple events.
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A total of 71 catheters, accompanied by 112 positive
BCs, were implicated in the 65 MC-CRBSI episodes.The number of BCs submitted per episode and the char-
acteristics of the catheters are summarised in Table 4. A
total of 38% (27/71) of the catheters were a non-
Table 3 Antimicrobial exposure of patients with
MC-CRBSI events









Antimicrobial agents, according to class, to which patients were
exposed to# % (n = 131 exposure events)
Carbapenems 29.8 (39)
Glycopeptides 15.3 (20)
Polymyxins (colistin) 10.7 (14)
Antifungals 9.9 (13)
β-lactamase inhibitors (piperacillin/tazobactam) 6.9 (9)
Penicillin 4.6 (6)
Folate pathway inhibitors 3.8 (5)
Oxazolidnones (linezolid) 3.8 (5)
Aminoglycosides 3.1 (4)
Extended-spectrum cephalosporins 3.1 (4)
Non extended-spectrum cephalosporins 3.1 (4)
Rifampicin 2.3 (3)
β-lactamase inhibitors (amoxicillin/clavulanic acid) 1.5 (2)
Rifafour 0.8 (1)
Macrolides 0.8 (1)
Glycylcyclines (tigecycline) 0.8 (1)
#Carbapenems = ertapenem, meropenem and imipenem; glycopeptides =
teicoplanin and vancomycin; antifungals = fluconazole, amphotericin B and
voriconazole; folate pathway inhibitors = bactrim (sulfamethoxazole and
trimethoprim) and dapsone; extended-spectrum cephalosporins = ceftriaxone
(rocephin); non extended-spectrum cephalosporins = prophylactic cefazolin
(kefzol); macrolides = clarithromycin.
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in the subclavian vein. All catheters were non-cuffed and
not impregnated with antimicrobials.
Microbiology and susceptibility patterns
A total of 195 microorganisms were isolated in the 65
MC-CRBSI episodes. Five MC-CRBSI episodes were
polymicrobial. The combinations of the polymicrobial
infections were as follow: i) S. epidermidis and Achromo-
bacter species, ii) Klebsiella pneumoniae and Enterobac-
ter cloacae, iii) S. aureus and Enterococcus faecalis, iv)
S. epidermidis and Acinetobacter baumannii complex
and v) Pseudomonas aeruginosa and K. oxytoca. Forty-
nine percent (48.5%; 34/70) of the MC-CRBSI episodes
were caused by Gram-negative bacteria; 45.7% (32/70)
by Gram-positive bacteria and 5.7% (4/70) by Candidaspecies (Table 5). Complete antimicrobial susceptibility
patterns are described in Table 6 for the most prevalent
bacteria implicated in MC-CRBSI episodes. All Entero-
coccus isolates were sensitive to vancomycin. Proteus
mirabilis and Escherichia coli isolates were all extended-
spectrum β-lactamase producers.
Discussion
Catheter-related infections pose an unrecognised threat to
patient safety. The results of the study showed that labora-
tory surveillance plays an important role in establishing
baseline data of CRIs in a setting with limited resources.
The number of patient admissions or the number of in-
patient days can effectively describe the hospital-wide
prevalence of these infections, especially where the collec-
tion of catheter days is problematic, as previously showed
by Rodríguez-Créixems and colleagues [18].
Comparing MC-CRBSI rates between surveillance net-
works are difficult, since the numerator (i.e. case defin-
ition of a CRI) and the denominators (i.e. 1 000 catheter
days, in-patient days or admissions) applied, vary greatly.
If one compare our MC-CRBSI rate (10.1 per 1 000
catheter days; 0.57 per 1 000 in-patient days or 3.7 per 1
000 admissions), regardless of the reporting denomin-
ator, to studies in Europe (2.1 per 1 000 catheter days)
[19], Spain (2.5 per 1 000 admissions) [18], Israel (0.21
per 1 000 in-patient days) [22] and by the International
Nosocomial Infection Control Consortium (4.8 per 1
000 catheter days) [23], our MC-CRBSI rate was higher.
Reasons argued to contribute to a higher CRI rate in-
cludes: i) a low nurse-to-patient ratio, ii) a lack of educa-
tion, iii) nurse inexperience and iv) a lack of infection
control legislation [4]. In South Africa, a survey of public
medical and surgical unit nurses showed that the nurse-
to-patient ratio ranged from 8.75 to 32 [17], whereas a
national audit showed that there are 0.3 trained ICU
nurses per ICU/high care bed [24]. Furthermore, only
25.6% (1 490/5 821) of ICU nurses were formally trained
in critical care and 42.8% (1 961/4 578) had zero to five
years of experience [24]. Draft legislation passed in 2008
by the South African National Department of Health, pro-
posed one infection control practitioner per 200 beds [13].
A human resource capacity survey followed and found
that no healthcare facility had the required number of in-
fection control practitioners and that 45.8% (116/253) of
the respondents were not formally employed; performed
infection control activities part-time or out of personal
interest and did not have additional support from an epi-
demiologist or a microbiologist [13].
Studies comparing the laboratory-based MC-CRBSI
rates with the classical hospital-based CLABSI rates are
scarce [18]. If one compares our laboratory-based MC-
CRBSI rate to the BCA campaign’s CLABSI rate, one
will note that the MC-CRBSI rate was higher in most of
Table 4 Characteristics of catheters that acted as the source of the MC-CRBSI episodes
Number of catheters per MC-CRBSI episode % (n = 71)
1 91.5 (65)
2 8.5 (6)
Type of catheter combinations % (n = 6)
CVP and arterial 83.6 (5)
CVP and VasCath 16.7 (1)










Type of catheter CVP Arterial VasCath Broviac Peripheral venous Umbilical
% (n = 51) % (n = 7) % (n = 7) % (n = 4) % (n = 1) % (n = 1)
Insertion site
Subclavian 66.7 (34) - 75 (3) - -
Peripheral - 28.6 (2) - - 100 (1) -
Radial - 71.4 (5) - - - -
Femoral 3.9 (2) - 14.3 (1) - - -
Internal jugular 21.6 (11) - 71.4 (5) - - -
Umbilical - - - - - 100 (1)
Unknown 7.8 (4) - 14.3 (1) 25 (1) - -
Physical length of the catheter
Short 94.1 (48) 100 (7) 100 (7) 100 (4) 100 (1) 100 (1)
Long 3.9 (2) - - - - -
Unknown 1.9 (1)
Type of vessel occupied
Central 100 (51) - 100 (7) 100 (4) - -
Arterial - 100 (7) - - - -
Peripheral venous - - - - 100 (1) 100 (1)
Insertion site pathway to the vessel
Non-tunnelled 88.2 (45) 100 (7) 85.7 (6) 100 (4) 100 (1) 100 (1)
Tunnelled 9.8 (5) - 14.3 (1) - - -
Unknown 1.9 (1) - - - -
Number of lumens
1 - 100 (7) - 25 (1) 100 (1) -
2 9.8 (5) - 28.6 (2) 25 (1) - 100 (1)
3 84.3 (43) - 71.4 (5) 25 (1) - -
Unknown 5.8 (3) - - 25 (1) - -
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Table 4 Characteristics of catheters that acted as the source of the MC-CRBSI episodes (Continued)
Length of catheterisation
% Unknown 17.6 (9) 71.4 (5) 14.3 (1) 0 0 100
Number of days (mean ± SD) 12.0 (5.4) 8.5 (2.1) 11.5 (5.5) 11 (6.8) 9 (n/a) -
BCs = blood culture(s); CVP = central venous catheter; SD = standard deviation.
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CLABSI surveillance tends to overestimate the actual
CRI rate, whereas laboratory-based MC-CRBSI tends to
underestimate the actual CRI rate [25]. However, an im-
portant contributing factor, which will explain the differ-
ence between the two rates, is the point at which the CRI
incidence is measured. Laboratory-based MC-CRBSI rates
are measured at the point of catheter removal, whereas
hospital-based CLABSI rates are measured at the point of
catheter insertion. Comparison of CLABSI rates with MC-
CRBSI rates may in future be used as a measurement to
evaluate the effectiveness of catheter maintenance prac-
tices against catheter insertion practices. The two wards
with a higher CLABSI rate and a lower MC-CRBSI rate
had a low number of catheter tips accompanied by BCsTable 5 Distribution of microorganisms implicated in MC-CRB
Aetiological agent % (n = number of isolates) % (n
Gram-positive bacteria
Staphylococci
S. epidermidis 28.2 (55) 25.7
S. aureus 8.2 (16) 10 (7
S. haemolyticus 4.1 (8) 4.29
Enterococci
E. faecalis 4.1 (8) 4.29
E. faecium 1.0 (2) 1.43
Gram-negative bacteria
Environmental gram-negatives
Acinetobacter baumannii complex 17.9 (35) 20 (1
Pseudomonas aeruginosa 7.2 (14) 7.14
Stenotrophomonas maltophilia 1.5 (3) 1.43
Achromobacter species 1.0 (2) 1.43
Enterobacteriaceae
Enterobacter cloacae 8.7 (17) 7.14
Klebsiella pneumoniae 6.2 (12) 7.14
Klebsiella oxytoca 2.6 (5) 1.43
Escherichia coli 2.6 (5) 1.43
Proteus mirabilis 1.5 (3) 1.43
Fungi
Candida species
C. albicans 3.6 (7) 4.29
C. parapsilosis 1.5 (3) 1.43
*Five MC-CRBSI events were polymicrobial, which will explain why the total numbewithin 48 h (Table 1) and microbiological documentation,
as such, is known to bias the true CRI rate [26].
Staphylococcus epidermidis was the most prevalent
aetiological agent, followed by Acinetobacter baumannii
complex. It can be argued that the criteria to include a
single positive BC for common commensals can inflate
the prevalence of S. epidermidis. However, the genetic
relationship between the catheter tip and BC isolates of
S. epidermidis isolates was confirmed with pulsed-field
gel electrophoresis. A notable exception to the distribu-
tion of CRI pathogens in the study is the predominance
of A. baumannii. Enterococci and Candida species are
more predominant in the USA, whereas Pseudomonas
aeruginosa and Escherichia coli are more predominant
in Europe [27,28]. The high proportion of the MC-SI episodes

















r of MC-CRBSI-events is divided by 70.
Table 6 Antimicrobial susceptibility profiles of microorganisms implicated in MC-CRBSI episodes
Antimicrobial susceptibility profile














Anti-staphylococcal β-lactams (oxacillin) 96 75 - - - -
Penicillin (ampicillin) - - - - - 100
β-lactamase inhibitors (amoxicillin/clavulanic acid) - - 100 - - 33
β-lactamase inhibitors (piperacillin/tazobactam) - - - 53 36 33
Cephamycins (cefoxitin) - - - - - 17
Non-ES cephalosporins (cefuroxime) - - - 71 - 33
ES cephalosporins (cefotaxime#, ceftazidime, cefepime) - - 100 53 21 33
Carbapenems (ertapenem#, meropenem, imipenem) - - 100 18 36 0
Aminoglycosides (amikacin*, gentamicin) 80 63 86 0 14 17
Fluoroquinolones (ciprofloxacin, moxifloxacin^) 55 75 49 0 14 17
Macrolides (erythromycin) 84 75 - - - -
Linosamides (clindamycin) 76 63 - - - -
Linezolid 0 0 - - - -
Glycopeptides (teicoplanin, vancomycin) 0 0 - - - -
Tetracycline 93 63 - - - -
Glycylcycline (tigecycline) 0 0 3 12 - 17
Fusidic acid 24 0 - - - -
Rifampicin 47 19 - - - -
Polymyxins (colistin) - - 0 6 14 0
Folate pathway inhibitors
(trimethoprim/ sulphamethoxazole)
78 75 - 12 - 17
Acquired resistance profiles
S 11 25 0 47 79 67
MDR 89 75 0 53 7 33
XDR 0 0 100 0 0 0
PDR 0 0 0 0 14 0
ES = extended-spectrum; S = sensitive.
MDR = multidrug-resistant, non-susceptible to ≥1 agent in ≥ 3 antimicrobial categories.
XDR = extensively drug-resistant, non-susceptible to ≥ 1 agent in all but ≤ 2 antimicrobial categories.
PDR = pandrug-resistant, non-susceptible to all antimicrobial agents tested [20].
- = not applicable to the specific bacteria, #not tested (n/t) for in P. aeruginosa, *n/t for in Gram-positive bacteria, ^n/t for in Gram-negative bacteria.
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gestive of a potential bias either at institutional level or on
patient-level. A study by Bouza and colleagues showed
that patients with a Gram-negative CRI were more likely
to have an underlying gastro-intestinal condition and were
previously exposed to antimicrobials, which were similar
to the patients involved in the current study [29].
A shift in the predominance of CRI pathogens, from
Gram-positive to Gram-negative bacteria, is widely re-
ported, which suggests that central line insertion bun-
dles are more effective in reducing Gram-positive CRI
than Gram-negative CRI [18,22,30-32]. The high preva-
lence of S. epidermidis CRI therefore implies failure to-
wards central line insertion bundle adherence. Urgent
attention needs to be paid to the education and trainingof healthcare personnel involved in catheter insertion,
not only to decrease the rate of MC-CRBSI, but to en-
sure patient safety.
Acinetobacter baumannii is listed by the Infectious
Disease Society of America as one of the six top-priority
dangerous microorganisms, which makes the predomin-
ance of this pathogen in the study a matter of concern.
The hospital environment (i.e. bed rails, mattresses, med-
ical equipment, colonised or infected patients and the
hands of healthcare workers) is an ecological niche for
A. baumannii and resistance to desiccation, disinfections
and antimicrobials makes eradication of this pathogen dif-
ficult [33]. All A. baumannii isolates was defined XDR in
the study, with isolates only being susceptible to colistin.
Although empirical antibiotic therapy for Gram-negative
Strasheim et al. BMC Infectious Diseases  (2015) 15:5 Page 9 of 10CRIs is based on local epidemiology, caution should be
exercised in recommending colistin monotherapy in
the management of CRI patients. Colistin-resistance in
A. baumannii, which is associated with the inappropriate
use thereof, can emerge rapidly, due to chromosomal mu-
tations [34]. Combination therapy of colistin and a carba-
penem should rather be used to prevent the emergence
of colistin-resistant A. baumannii [34]. Extensive envir-
onmental decontamination, such as daily chlorhexidine
bathing and oral care of colonised or infected patients,
as well the use of an oxidizing disinfectant (Virkon S;
potassium peroxomonosulphate 50%, sodium alkyl ben-
zene sulphonate 15% and sulphamic acid 5%), should be
considered to control and prevent further spread of
A. baumannii [35,36].
The study had a number of limitations. First, it is im-
portant to note that the definition applied is highly spe-
cific and that some cases of CRIs might have been
missed. In future, criteria, such as the clinical improve-
ment of the patient after line removal, which is suggest-
ive of a CRI and other diagnostic methods, such as
differential time to positivity, which might be more ap-
propriate in oncology and haematological patient popu-
lations, should be included to obtain a more reliable CRI
rate. Second, the Acute Physiological Assessment and
Chronic Health Evaluation (APACHE) II severity of ill-
ness score could not be determined and no comment
can be made on the appropriateness of antimicrobial
chemotherapy, since the initial reason for therapy, dos-
age, the administration route and the duration of treat-
ment were unknown. However, it is known that the
majority of patients were exposed to two or more anti-
microbial agents during hospitalisation, such as carba-
penems and glycopeptides. This is worrying, due to the
strong association between the over usage of antimicro-
bials and the selection of resistance in microorganisms.
The device utilisation rate could not be calculated, since
the number of in-patient days, for the wards where
catheter days were collected, was unknown. Lastly, the
study cannot be extrapolated to the entirety of South
Africa, since a single institution is not representative of
the country.Conclusions
The microbiology laboratory can obtain baseline data on
the CRI rates in a setting with limited resources by follow-
ing the catheter culture requests submitted to the labora-
tory. The occurrence of MC-CRBSI can be decreased by
implementing and adhering to central line insertion and
maintenance bundles, strictly following hand hygiene pro-
cedures, as well as environmental decontamination, not
only to prevent CRIs, but to limit the spread of multidrug-
resistant bacteria.Abbreviations
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